Transthyretin sequesters amyloid beta protein and prevents amyloid formation

Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8368-72. doi: 10.1073/pnas.91.18.8368.

Abstract

The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid beta protein (A beta) in the brain and cerebrovasculature. However, the A beta is found in a soluble form in cerebrospinal fluid in healthy individuals and patients with Alzheimer disease. We postulate that sequestration of A beta precludes amyloid formation. Failure to sequester A beta in Alzheimer disease may result in amyloidosis. When we added A beta to cerebrospinal fluid of patients and controls it was rapidly sequestered into stable complexes with transthyretin. Complexes with apolipoprotein E, which has been shown to bind A beta in vitro, were not observed in cerebrospinal fluid. Additional in vitro studies showed that both purified transthyretin and apolipoprotein E prevent amyloid formation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Amyloid Neuropathies / prevention & control*
  • Amyloid beta-Peptides / metabolism*
  • Computer Graphics
  • Humans
  • In Vitro Techniques
  • Models, Molecular
  • Molecular Sequence Data
  • Prealbumin / cerebrospinal fluid
  • Prealbumin / metabolism*
  • Protein Binding

Substances

  • Amyloid beta-Peptides
  • Prealbumin